Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument

Value in Health

Volumn 12, Issue 1, 2009, Pages 109-117

  Rofail, Diana ^a   Abetz, Linda ^a   Viala, Muriel ^a   Gait, Claire ^a   Baladi, Jean Francois ^b   Payne, Krista ^c  

^a MAPI VALUES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Caro Research Institute   (Canada)

Author keywords

Adherence; Instrument; Iron chelation therapy; Oral administration; Satisfaction; SICT; Subcutaneous administration

Indexed keywords

IRON;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONCURRENT VALIDITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; INTERNAL CONSISTENCY; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMETRY; RETROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; THALASSEMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BENZOIC ACIDS; FEMALE; GREAT BRITAIN; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; TRIAZOLES; UNITED STATES; YOUNG ADULT;

EID: 58849157398     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00390.x     Document Type: Article

References (38)

1. Vichinsky EP. Changing patterns of thalassemia worldwide. Ann N Y Acad Sci 2005 1054 : 18 24.
2. Serjeant GR. Sickle-cell disease. Lancet 1997 350 : 725 30.
3. Cazzola M, Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005 352 : 536 8.
4. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997 89 : 739 61.
5. Harvard Medical School. Effects of iron overload: hemochromatosis, tranfusional iron overload. Available from: http://sickle.bwh.harvard.edu/index. html [Accessed August, 2006 V, Piga A. Results of long-term iron-chelating therapy. Acta Haematologica 1996 91 : 26 36.
6. Vidler V. Compliance with iron chelation therapy in beta thalassaemia. Paediatr Nurs 1998 10 : 17 8.
7. Abetz L, Baladi JF, Jones P, Rofail D. The Impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes 2006 4 : 73.
8. Arboretti R, Tognoni G, Alberti D Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol 2001 56 : 915 22.
9. Ismail A, Campbell MJ, Ibrahim HS, Jones GL. Health related quality of life in Malaysian children with thalassaemia. Health Qual Life Outcomes 2006 4 : 39.
10. Payne KA, Desrosiers MP, Caro JJ, et al. Clinical and economic burden of infused iron chelation therapy (ICT) in the United States. Transfusion 2007 47 : 1820 9.
11. Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol 2002 20 : 2441 52.
12. Hasan SP, Hashmi S, Alhassen M, et al. Depression in sickle cell disease. J Natl Med Assoc 2003 95 : 533 7.
13. Rebulla P. Transfusion reactions in thalassemia. A survey from the Cooleycare programme. The cooleycare cooperative group. Haematologica 1990 75 (Suppl. 5 S122 7.
14. Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol 2001 38 : 360 6.
15. Alymara V, Bourantas D, Chaidos A, et al. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Hematol J 2004 5 : 475 9.
16. Ward A, Caro JJ, Green TC, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol 2002 2 : 3.
17. Caro JJ, Ward A, Green TC, et al. A. Impact of thalassemia major on patients and their families. Acta Haematologica 2002 107 : 150 7.
18. Ratip S, Skuse D, Porter J, et al. Psychosocial and clinical burden of thalassaemia intermedia and its implications for prenatal diagnosis. Arch Dis Child 1995 72 : 408 12.
19. Atkin K, Ahmad WIU. Family caregiving and chronic illness: how parents cope with a child with sickle cell disorder or thalassaemia. Health Soc Care Community 2000 8 : 57 69.
20. Modell B, Khan M, Darlison M. Survival in beta-thalassemia major in the UK: data from the UK thalassemia register. Lancet 2000 355 : 2051 2.
21. Vichinsky E, Onyekwere O, Porter J, et al. Patient reported outcomes of deferasirox (exjade ICL670) in comparison with deferoxamine in sickle cell disease patients with transfusional hemosiderosis: a randomised comparative, open label phase II Trial. Br J Haematol 2006 136 : 501 8.
22. Cappellini MD, Bejaoui M, Agaoglu L, et al. Patient reported outcomes of deferasirox (exjade, icl670) in comparison with deferoxamine in beta-thalassemia patients with transfusional hemosiderosis: a randomized comparative, open-label phase III trial. Br J Haematol 2006 106 : Abstract 2704.
23. Olivieri N, Brittenham GM, McLaren CE, et al. Long-term safety and effectivness of iron chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998 339 : 417 23.
24. Caro JJ, Huybrechts K, Green TC. Estimates of the effect on hepatic iron of oral deferiprone compared to subcutaneous desferrioxamine for treatment of iron overload in thalassaemia major: a systematic review. BMC Blood Disord 2002 2 : 4.
25. Rofail D, Viala M, Baladi J-F, et al. Satisfaction with ICT predicts never thinking about stopping chelation therpay in patients with iron overload. Ann Oncol 2006 17 (Suppl. 9 ix 193 Poster Presented at ESMO, Istanbul, Turkey).
26. Rofail D, Revera S, Scalone L, et al. Satisfaction with iron chelation therapy and its impact on adherence in patients with beta thalassemia major: results from the ITHACA study. Poster Presented at ISPOR, Florence, 2006.
27. Hall J, Dornan MC. Patient sociodemographic characteristics as predictors of satisfaction with medicine. Soc Sci Med 1990 30 : 811 8.
28. Linder-Pelz SU. Toward a theory of patient satisfaction. Soc Sci Med 1982 16 : 577 82.
29. Staquet NJ, Hays RD, Fayers PN. Quality of life assessments in clinical trials: methods and practice. Oxford : Oxford University Press, 1998.
30. Guy RG, Norvell M. The neutral point on a likert scale. J Psychol 1977 95 : 199 204.
31. Ray JJ. Acquiescence and problems with forced-choice scales. J Soc Psychol 1990 130 : 397 99.
32. Ware JE Jr., Sherbourne, CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 30 : 473 83.
33. Landgraf JM, Abetz L, Ware JE. The CHQ: a user's Manual (2nd ed Boston, MA : The Health Institute, 1996.
34. Hays RD, Stewart AL. Sleep measures. In : Stewart AL, Ware JE, eds. Measuring Functioning and Well-being. The Medical Outcomes Study Approach. Durham & London : Duke University Press, 1992.
35. Nunnally JC. Psychometric Theory (2nd ed New York : McGraw Hill, 1978.
36. Atkinson MJ, Kumar R, Cappelleri JC, Hass S. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM Version II) among outpatient pharmacy consumers. Value Health 2005 8 (Suppl. 1 S1 60.
37. Treadwell M, Law AW, Sung J, et al. Barriers to adherence of derferoxamine usage in sickle cell disease. Paediatr Blood Cancer 2005 44 : 500 7.
38. Tabachnick BG, Fidell LS. Using Multivariate Statistics (4th ed Needham Heights, MA : Allyn & Bacon, 2001.